Andres Perissinottti

Dr. Andres Perissinottti

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2019 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
GSGemma Salvadó
Gemma Salvadó
JMJosé Luis Molinuevo
José Luis Molinuevo
ABAnna Brugulat-Serrat
Anna Brugulat-Serrat
CFCarles Falcon
Carles Falcon
OGOriol Grau
Oriol Grau
JGJuan Domingo Gispert
Juan Domingo Gispert
The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Centiloid thresholds that maximize the agreement against core Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers in two large independent cohorts. A total of 516 participants of the ALFA+ Study (N = 205) and ADNI (N = 311) underwent amyloid PET imaging ([18F]flutemetamol and [18F]florbetapir, respectively) and core AD CSF biomarker determination using Elecsys® tests. Tracer uptake was quantified in Centiloid units (CL). Optimal Centiloid cut-offs were sought that maximize the agreement between PET and dichotomous determinations based on CSF levels of Aβ42, tTau, pTau, and their ratios, using pre-established reference cut-off values. To this end, a receiver operating characteristic analysis (ROC) was conducted, and Centiloid cut-offs were calculated as those that maximized the Youden’s J Index or the overall percentage agreement recorded. All Centiloid cut-offs fell within the range of 25–35, except for CSF Aβ42 that rendered an optimal cut-off value of 12 CL. As expected, the agreement of tau/Aβ42 ratios was higher than that of CSF Aβ42. Centiloid cut-off robustness was confirmed even when established in an independent cohort and against variations of CSF cut-offs. A cut-off of 12 CL matches previously reported values derived against postmortem measures of AD neuropathology. Together with these previous findings, our results flag two relevant inflection points that would serve as boundary of different stages of amyloid pathology: one around 12 CL that marks the transition from the absence of pathology to subtle pathology and another one around 30 CL indicating the presence of established pathology. The derivation of robust and generalizable cut-offs for core AD biomarkers requires cohorts with adequate representation of intermediate levels. ALFA+ Study, NCT02485730 ALFA PET Sub-study, NCT02685969

2 May 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
AIAlex Iranzo
Alex Iranzo
AMAngela Mammana
Angela Mammana
AMAmaia Muñoz-Lopetegi
Amaia Muñoz-Lopetegi
SDSofia Dellavalle
Sofia Dellavalle
GMGerard Mayà
Gerard Mayà
PPPiero Parchi
Piero Parchi
Background and Objectives. Real-time quaking-induced conversion (RT-QuIC) assay detects misfolded α-synuclein in the skin and CSF of patients with the synucleinopathies Parkinson disease and dementia with Lewy bodies. Isolated REM sleep behavior disorder (IRBD) constitutes the prodromal stage of these synucleinopathies. We aimed to compare the ability of RT-QuIC to identify misfolded α-synuclein in the skin and CSF of IRBD patients. Methods. Cross-sectional study where consecutive patients with polysomnographic-confirmed IRBD and age-matched controls without RBD underwent skin biopsy and lumbar puncture the same day. 3-mm skin punch biopsies were obtained bilaterally in cervical region from dorsal C7 and C8 dermatomes, and in distal legs. RT-QuIC assessed misfolded α-synuclein in these six skin sites and CSF. Results. We recruited 91 IRBD patients and 41 controls. In skin, sensitivity to detect misfolded α-synuclein was 76.9% (95%CI 66.9–85.1), specificity 97.6% (95%CI 87.1–99.9) positive predictive value 98.6% (95%CI 91.0-99.8), negative predictive value 65.6% (95%CI 56.6-73.6) and accuracy 83.3% (95%CI 75.9–89.3). In CSF, sensitivity was 75.0% (95% CI 64.6–83.6), specificity 97.5% (95%CI 86.8–99.9) positive predictive value 98.5% (95%CI 90.5-99.8), negative predictive value 63.9% (95%CI 55.2-71.9) and accuracy 82.0% (95%CI 74.3–88.3). Results in skin and CSF samples showed 99.2% agreement. Compared with negative patients, RT-QuIC α-synuclein positive patients had higher likelihood ratio of prodromal Parkinson disease (p<0.001) and showed more frequently hyposmia (p<0.001), DAT-SPECT deficit (p=0.002) and orthostatic hypotension (p=0.014). No severe or moderate adverse effects were reported. There was no difference between percentage of participants reporting mild adverse events secondary to skin biopsy or lumbar puncture (9.1% versus 17.2%; p=0.053).83% participants stated they would accept to undergo again skin biopsy and 80% lumbar puncture, for research purposes. Discussion. Our study in IRBD shows that 1) RT-QuIC detects misfolded α-synuclein in skin and CSF with similar high sensitivity, specificity, and agreement, 2) α-synuclein RT-QuIC positivity is associated with supportive features and biomarkers of synucleinopathy, and 3) skin punch biopsy and lumbar puncture have comparable mild adverse effects, tolerance, and acceptance. α-synuclein RT-QuIC in skin or CSF might represent a patient selection strategy for future neuroprotective trials targeting α-synuclein in IRBD. Classification of Evidence: This study provides Class III evidence that RT-QuIC detected misfolded α-synuclein in the skin and CSF distinguishes patients with IRBD from controls.

23 November 2021 in Neurology
Verified
Journal Article
Open access
PDF file
MMMarta Milà-Alomà
Marta Milà-Alomà
ABAnn Brinkmalm
Ann Brinkmalm
NANicholas J. Ashton
Nicholas J. Ashton
HKHlin Kvartsberg
Hlin Kvartsberg
MSMahnaz Shekari
Mahnaz Shekari
MVMarc Vilanova
Marc Vilanova
Background and Objectives To determine whether CSF synaptic biomarkers are altered in the early preclinical stage of the Alzheimer continuum and associated with Alzheimer disease (AD) risk factors, primary pathology, and neurodegeneration markers. Methods This cross-sectional study was performed in the Alzheimer9s and Families (ALFA+) cohort, comprising middle-aged cognitively unimpaired participants. CSF neurogranin and growth-associated protein-43 (GAP-43) were measured with immunoassays, and synaptosomal-associated protein-25 (SNAP-25) and synaptotagmin-1 were measured with immunoprecipitation mass spectrometry. AD CSF biomarkers β-amyloid (Aβ)42/40, phosphorylated tau (p-tau), and total tau and the neurodegeneration biomarker neurofilament light chain (NfL) were also measured. Participants underwent structural MRI and fluorodeoxyglucose and Aβ PET imaging. General linear modeling was used to test the associations between CSF synaptic biomarkers and risk factors, Aβ pathology, tau pathology, and neurodegeneration markers. Results All CSF synaptic biomarkers increased with age. CSF neurogranin was higher in females, while CSF SNAP-25 was higher in APOE ε4 carriers. All CSF synaptic biomarkers increased with higher Aβ load (as measured by CSF Aβ42/40 and Aβ PET Centiloid values), and it is important to note that the synaptic biomarkers were increased even in individuals in the earliest stages of Aβ deposition. Higher CSF synaptic biomarkers were also associated with higher CSF p-tau and NfL. Higher CSF neurogranin and GAP-43 were significantly associated with higher brain metabolism but lower cortical thickness in AD-related brain regions. Discussion CSF synaptic biomarkers increase in the early preclinical stages of the Alzheimer continuum even when a low burden of Aβ pathology is present, and they differ in their association with age, sex, APOE ε4, and markers of neurodegeneration. Trial Registration Information ClinicalTrials.gov Identifier NCT02485730.

1 January 2013 in Gynecologic Oncology
Verified
Journal Article
Closed access
ATAureli Torné
Aureli Torné
P(PAHISA, JAUME (ICGON)
PAHISA, JAUME (ICGON)
SVSergi Vidal-Sicart
Sergi Vidal-Sicart
SMSergio Martínez-Roman
Sergio Martínez-Roman
PPPilar Paredes
Pilar Paredes
Jaume OrdiJaume Ordi
Jaume Ordi

5 May 2014 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
APAndres Perissinottti
Andres Perissinottti
XSXavier Setoain
Xavier Setoain
JAJavier Aparicio
Javier Aparicio
SRSebastiá Rubí
Sebastiá Rubí
BFBerta Marti Fuster
Berta Marti Fuster
FPFrancesca Pons
Francesca Pons
A precise assessment of the drug-resistant epileptic pediatric population for surgical candidacy is often challenging, and to date there are no evidence-based guidelines for presurgical identification of the epileptogenic zone. To evaluate the usefulness of radionuclide imaging techniques for presurgical evaluation of epileptic pediatric patients, we compared the results of video-electroencephalography (EEG), brain MR imaging, interictal SPECT, ictal SPECT, subtraction ictal SPECT coregistered to MR imaging (SISCOM), and interictal PET with (18)F-FDG. Fifty-four children with drug-resistant epilepsy who had undergone video-EEG monitoring, brain MR imaging, interictal and ictal brain perfusion SPECT, SISCOM, and (18)F-FDG PET were included in this study. All abnormal findings revealed by these neuroimaging techniques were compared with the presumed location of the epileptogenic zone (PEZ) as determined by video-EEG and clinical data. The proportion of localizing studies for each technique was statistically compared. In the 18 patients who underwent resective brain surgery, neuroimaging results were compared with histopathology results and surgical outcome. SISCOM and (18)F-FDG PET concordance with the PEZ was significantly higher than MR imaging (P < 0.05). MR imaging showed localizing results in 21 of 54 cases (39%), SISCOM in 36 of 54 cases (67%), and (18)F-FDG PET in 31 of 54 cases (57%). If we consider SISCOM and (18)F-FDG PET results together, nuclear medicine imaging techniques showed coinciding video-EEG results in 76% of patients (41/54). In those cases in which MR imaging failed to identify any epileptogenic lesion (61% [33/54]), SISCOM or (18)F-FDG PET findings matched PEZ in 67% (22/33) of cases. SISCOM and (18)F-FDG PET provide complementary presurgical information that matched video-EEG results and clinical data in three fourths of our sample. SISCOM was particularly useful in those cases in which MR imaging findings were abnormal but no epileptogenic lesion was identified. Radionuclide imaging techniques are both useful and reliable, extending the possibility of surgical treatment to patients who may have been discouraged without a nuclear medicine approach.

11 June 2016 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MMMaria Mayoral
Maria Mayoral
BMBerta Marti‐Fuster
Berta Marti‐Fuster
MCMar carreño
Mar carreño
JCJosep L. Carrasco
Josep L. Carrasco
NBNuria Bargallo
Nuria Bargallo
XSXavier Setoain
Xavier Setoain